Clayton, NC, United States of America

Christopher Kelly Biggers

This inventor holds 1 USPTO granted patent. Top assignee: Eli Lilly and Company. Active years: 2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher Kelly Biggers. Retrieved from https://idiyas.com/inventor/christopher-kelly-biggers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Christopher Kelly Biggers

Introduction

Christopher Kelly Biggers is an accomplished inventor based in Clayton, NC (US). He has made significant contributions to the field of medical science, particularly in the development of treatments for various health conditions. His innovative work has led to the creation of a patent that addresses critical health issues.

Latest Patents

Biggers holds a patent for melanocortin receptor agonists, which are compounds that have shown promise in the treatment of obesity, diabetes, and sexual dysfunction in both males and females. This invention is a testament to his dedication to improving health outcomes through scientific innovation.

Career Highlights

Biggers is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His role at Eli Lilly allows him to collaborate with other experts in the field and contribute to groundbreaking research and development efforts.

Collaborations

Some of his notable coworkers include Karin Briner and Christopher William Doecke. Their collective expertise enhances the innovative environment at Eli Lilly, fostering advancements in medical treatments.

Conclusion

Christopher Kelly Biggers exemplifies the spirit of innovation in the pharmaceutical industry. His work on melanocortin receptor agonists highlights the potential for scientific advancements to address pressing health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…